1 A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. 2  Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear.
Bravecto (fluralaner) is a systemic antiparasitic drug introduced to the veterinary market by Merck in 2014. A 7 March 2014 study published in the journal Parasites & Vectors (based upon a study of 32 beagles treated with fluralaner) observed no serious adverse side effects attributed to the medication:
As the BRAVECTO social media warning spread among dog owners, the Wilson Street Veterinary Facebook page published a status update addressing rumors about the drugâs safety. In that update, Dr. Michael Mogavero stated that the drug had been extensively tested prior to its release and had proved safe for dogs: